Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.
Phase 4
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2010-08-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 121
- Registration Number
- NCT00770445
Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.
Phase 2
Completed
- Conditions
- Oxidative StressCoronary Artery DiseaseType 2 Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2010-07-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 63
- Registration Number
- NCT00771004
Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease
Phase 2
Completed
- Conditions
- Cardiovascular Diseases
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2010-07-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 148
- Registration Number
- NCT00770575
Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2010-07-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 91
- Registration Number
- NCT00770952
Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.
Phase 2
Completed
- Conditions
- InflammationHypertension
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2010-07-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 172
- Registration Number
- NCT00770497
Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 302
- Registration Number
- NCT00763022
Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 316
- Registration Number
- NCT00762112
Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 348
- Registration Number
- NCT00762190
Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15
- Registration Number
- NCT00762957
A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers
Phase 3
Terminated
- Conditions
- Stomach UlcerDuodenal Ulcer
- Interventions
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 461
- Registration Number
- NCT00762359
© Copyright 2025. All Rights Reserved by MedPath